Ensitrelvir Reduced COVID After Household Exposure
In SCORPIO-PEP, symptomatic COVID-19 occurred in 3% vs 9% of household contacts by day 10.
-
By
-
Kathryn Wighton
-
May 27, 2026
-
Clinical Scorecard: Ensitrelvir Reduced Covid After Household Exposure
At a Glance
| Category | Detail |
|---|
| Condition | |
| Key Mechanisms | |
| Target Population | |
| Care Setting | Household and clinical trial settings, including specific trial context. |
Key Highlights
- Clarify that the 67% reduction refers to relative risk.
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
- Monitor for adverse events and symptom development for at least 10 days post-exposure, including specific adverse events.
Risks
Patient & Prescribing Data
Emphasize the importance of early treatment initiation within 72 hours of symptom onset in the index patient for enhanced efficacy.
Clinical Best Practices
- Monitor for changes in cholesterol levels specifically in ensitrelvir recipients.
Related Resources & Content
